IGMS (igmbio.com) Net Profit

IGMS (igmbio.com) - company brandmark

IGM Biosciences, Inc. (IGMS) is implementing robotic screening to develop anti-cancer antibodies, thereby minimizing human error. The company's commercial results clearly demonstrate yield dynamics, where the value -0.05 captures this metric. The safety of biologics is ensured by ultra-reliable cold chain logistics. Meanwhile, management has successfully pivoted the development of its R&D core toward the promising market of autoimmune pathology therapies.

IGMS (IGM Biosciences, Inc.) Net Profit history from 07/04/2022 to 08/24/2025

Analytical breakdowns and data insights for company igmbio.com (IGMS)

- price and consensus price forecast:
Stock Quotes IGM Biosciences|IGMS - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization IGM Biosciences, Inc.|IGMS - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share IGM Biosciences|IGMS - Book Capitalization|Market Capitalization to Book Value igmbio.com|IGMS - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio IGM Biosciences, Inc.|IGMS - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio IGM Biosciences|IGMS - Company Total Debt|Debts to Book Capitalization IGM Biosciences, Inc.|IGMS - Company Long-Term Debt|Company Short-Term Indebtedness IGM Biosciences|Immediate Liquidity igmbio.com
- net income and valuation multiples indicators:
IGMS - Net Profit
Summary company analysis:IGM Biosciences, Inc.
Core merchandise of IGM Biosciences Inc.

The net economic effect dynamics of IGM Biosciences, Inc. (IGMS) reflect the actual speed of cash inflows, neutralizing the time lag of traditional reporting through daily monitoring of actual profit. This metric measures the current operating return of the business, allowing investors to assess the efficiency of R&D expenditures amid the platform's pivot toward autoimmune diseases, while the market value of assets already prices in existing cash reserves.

Main competitors

Net Income argenx BVBA|BNTX (BioNTech SE) - Net Profit|Net Profit Abivax Pharma|Net Income ADMA (ADMA Biologics, Inc.)|PTGX (Protagonist Therapeutics, Inc.) - Final Profit|Net Profit IMVT (Immunovant Corp)|Net Financial Result Kiniksa Corp (KNSA)|GRFS - Company Net Income|adaptivebiotech.com (ADPT) - Net Income|Celldex Therapeutics, Inc. (CLDX) - Company Net Income|Net Income Aurinia Pharmaceuticals Inc|Net Income BCRX|Net Profit Vera Corp|Company Net Income Dianthus Therapeutics (DNTH)|pharvaris.com - Company Profit|Net Profit ABCL (AbCellera Biologics Inc)|Tourmaline Bio Inc (TRML) - Company Net Income|Intrexon - Net Profit|Net Financial Result Pharming Corp PHAR|NKTR: Net Profit|Annual Net Income upstreambio.com UPB|Company Net Income Zenas Biopharma|Net Income Immunome Inc (IMNM)|Net Income GOSS (Gossamer Corp)|KALV (KalVista Corp) - Final Profit|Net Profit SEPN (Septerna Inc)|pieris.com - Company Net Income|Savara - Net Profit|Net Financial Result Rigel Pharma RIGL|AnaptysBio Corp (ANAB) - Company Net Income|Company Net Income Astria Corp (ATXS)|Company Net Income enGene Holdings Inc.|rapt.com (RAPT) - Net Financial Result|Net Profit JBIO|Net Income Aclaris Therapeutics Inc. ACRS|Net Profit KYTX (Kyverna)|Net Financial Result Tiziana Life Sciences, Ltd. (TLSA)|Cabaletta Bio, Inc. - Net Profit|Company Net Income ventyxbio.com|Theratechnologies (THTX) - Company Net Income|Company Profit AVTX|ELDN (Eledon) - Net Profit|Net Income Agenus, Inc (AGEN)|Net Profit CLYM|ZURA - Company Net Income|Company Net Income aTyr Pharma ATYR|Net Financial Result Adagene Inc (ADAG)|IMA: Net Income|Final Profit STTK (Shattuck Labs, Inc.)|EQ: Net Profit|CNTB - Net Financial Result|Company Net Income Immunic Therapeutics|Company Profit ATRA (Atara Biotherapeutics Inc)|Net Profit IFRX|Net Income X4 Pharmaceuticals, Inc XFOR|Adicet Bio, Inc. - Net Income|Net Financial Result Celularity Inc (CELU)|INmune Bio - Net Profit|Net Financial Result Barinthus Biotherapeutics PLC BRNS|KZR: Net Profit|Annual Net Income SAB Biotherapeutics Inc SABS|Company Net Income Akari Therapeutics|Net Income Enlivex Therapeutics, Ltd. (ENLV)|Company Net Income Q32 Bio Inc. (QTTB)|Net Financial Result GeoVax Labs|Company Net Income Edesa EDSA|IBIO (iBio Corporation) - Profit After Tax|Carisma Tx - Net Profit|Final Profit XTLB (xtlbio.com)|BOLT: Net Profit|HCW Biologics (HCWB) - Net Profit|Company Net Income Aptevo Therapeutics, Inc.|AIM: Final Profit|Company Net Income Aditxt (ADTX)|Net Income gribio.com GRI|Net Profit XRTX (XORTX Therapeutics)|Net Profit Vyome Holdings Inc. HIND|REVB: Net Income|Final Profit INDP (Indaptus Corp)|SCNI: Net Profit|CALI - Net Financial Result|Company Net Income Affimed NV|Net Income Allakos Therapeutics (ALLK)|Company Net Income HOOKIPA Pharma Inc. (HOOK)|Net Income iTeos Pharma ITOS|Ocean Biomedical, Inc. - Net Income|Net Profit tcbiopharm.com TCBP|THRD - Company Net Income